Our team is made up of researchers and clinicians from around the world, actively publishing peer-reviewed work on stem cells, exosomes, and cellular therapies. We aren’t a marketing arm dressed up as a research division — we’re a group of scientists and physicians committed to building the evidence base this field needs, one study, one publication, one protocol at a time.

That commitment shows up in a growing portfolio of IRB-approved research studies, running concurrently across the United States and internationally. These aren’t studies conducted quietly behind closed doors — they’re built to be shared. Regenerative therapy providers across the U.S. can participate directly, giving their own practices the benefit of structured, defensible, IRB-backed research infrastructure without having to build it themselves.